A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)-Reference-Cited by-同舟云学术

A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)

Published:2024-01 Issue: Volume:197 Page:113469
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Watanabe Satoshi^ORCID,Furuya Naoki^ORCID,Nakamura Atsushi,Shiihara Jun,Nakachi Ichiro^ORCID,Tanaka Hisashi^ORCID,Nakao Mika^ORCID,Minato Koichi,Seike Masahiro,Sasaki Shinichi^ORCID,Kisohara Akira,Takeuchi Susumu^ORCID,Honda Ryoichi,Takamura Kei,Kagamu Hiroshi^ORCID,Yoshimura Kenichi,Kobayashi Kunihiko^ORCID,Kikuchi Toshiaki^ORCID

Funder

Chugai Pharmaceutical

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies;Jordan;Cancer Discov,2017

2. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients;Liu;Cancer Sci,2017

3. Toward personalized treatment approaches for non-small-cell lung cancer;Wang;Nat Med,2021

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Therapy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel for Metastatic Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Resistance and EGFR Mutations;Cureus;2024-08-20

2. Immunotherapy for lung cancer;Pathology - Research and Practice;2024-02